StudyFinds' Dr. Faith Coleman explains what happens when patients stop taking popular weight loss medications.

A study using Swedish patient data found anti-obesity drugs were linked with fewer hospitalizations related to alcohol use, ...

Who knew weight loss and wine could be frenemies? My journey with Ozempic started as a bid to shed pounds, but it ...

New studies in JACC highlight improvements in cardiac structure and function among CABG patients, as well as changes in ...

But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD).

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

Strata Decision Technology data finds the number of bariatric surgeries in the Chicago area may have fallen by more than half ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...